Baxter International (BAX)
Health Care · Medical devices, specialty pharmaceuticals, and healthcare solutions
A diversified healthcare company producing sterile IV solutions, infusion systems, parenteral nutrition, inhaled anesthetics, surgical sealants, smart beds, and patient monitoring systems for hospitals and home care globally.
What Baxter International does
Baxter International manufactures and sells a broad portfolio of essential healthcare products including sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. These products are distributed to hospitals, nursing homes, ambulatory surgery centers, dialysis centers, doctor's offices, and patients at home in over 100 countries. The company recently divested its Kidney Care business (sold to Carlyle Group in January 2025 for $3.8 billion) and BioPharma Solutions business, and now operates through three reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Themes: ["Hospital infrastructure and critical care","Acute and chronic disease management","Connected care and digital health","Surgical support and hemostasis","Nutritional support therapies","Global healthcare access"]
Fundamentals
- Price$22.46 as of 2026-07-09 close
- Market cap$11.5B as of 2026-07-10
- 1-year return-24.7% as of 2026-07-09 close
- Net margin-9.7% as of 2026-07-10
- Gross margin+30.7% as of 2026-07-10
- ROE-16.4% as of 2026-07-10
- Debt / equity1.57 as of 2026-07-10
- Revenue growth (YoY)-4.8% as of 2026-07-10
- Revenue CAGR (3y)+3.8% SEC XBRL
- Beta0.61 as of 2026-07-10
Dividend: yield +0.2%; 1-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Significant debt burden ($8.6 billion long-term debt as of Q1 2026) and negative net margins (-9.7%) with continued operating losses in recent quarters, limiting financial flexibility","Revenue decline of 4.79% year-over-year with unprofitability in continuing operations, indicating difficulty in offsetting cost pressures and market headwinds","Recent major divestitures (Kidney Care and BioPharma Solutions) have created portfolio transition risks and reliance on debt repayment from divestiture proceeds, potentially constraining future investment capacity"]
Competitors & peers
- B. Braun
- Fresenius
- Abbott Laboratories (ABT)
- Hospira (part of Pfizer)
- Becton Dickinson (BDX)
- Medtronic (MDT)
- Philips Healthcare
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.